1. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers
Yao Chen & Wei Zhang & Wei-hua Huang & Zhi-rong Tan. Eur J Clin Pharmacol (2013) 69:1933–1938
The study had a randomized crossover design with two periods that were separated by a 2-week washout period. During the study periods, the volunteers received administrations of either 4 mg pitavastatin calcium, or 4 mg pitavastatin calcium in combination with 600 mg rifampin capsule swallowed by 150 ml water, then a series venous blood samples of 5 ml were collected into EDTA-containing tubes at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 h. After the washout period, the experiment was carried out by crossover. The plasma samples were separated by centrifugation and immediately stored in polypropylene tubes at −40 °C until analysis.
2. Determination of Pitavastatin in Human Plasma by LC–MS–MS
Jianzhong Shen-Tu, Xiao Xu, Jian Liu*. Chromatographia 2009, 69, May (No. 9/10)
We have developed a simple and rapid LC–MS–MS method using acetonitrile as protein precipitation solvent to determine pitavastatin in human plasma. Convenient sample preparation and high sensitivity are the main advantages of the technique. The method has been validated and applied successfully to a clinical study after single oral doses of 1, 2 and 4 mg pitavastatin calcium tablets.